№ lp_1_2_16593
File format: docx
Character count: 18961
File size: 92 KB
This clinical practice standard provides guidance on the use and administration of combination oral contraceptives in reproductive health clinics.
Year:
2025
Region / City:
USA
Theme:
Reproductive Health, Contraception
Document Type:
Clinical Practice Standard
Agency / Institution:
(insert AGENCY name)
Author:
(insert AGENCY name)
Target Audience:
Healthcare providers (MDs, NPs, PAs, DOs, NDs, RNs)
Period of Action:
Ongoing
Approval Date:
January 2025
Revision Date:
March 2017, January 2018, January 2019, January 2021, October 2022, January 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
Not specified
Region / City:
Chak Bhalwal, Jammu
Country:
India
Subject:
Contraception and family planning
Document Type:
Academic research study
Research Approach:
Qualitative research
Research Design:
Phenomenological research design
Author:
Nikita Sharma
Author Position:
Assistant Professor
Institution:
Maharishi Markandeshwar College of Nursing, Mullana, Ambala
Sample Size:
6 women
Target Population:
Women aged 35–50 years residing in a selected village of Jammu
Sampling Technique:
Convenience sampling
Data Collection Methods:
Interviews, socio-demographic profile forms, self-structured questionnaires
Key Topics:
Perception of contraceptives, choices of contraceptive methods, experiences with contraceptives, sources of information, unintended pregnancy, reasons for non-use of contraception
Religious Background of Participants:
Hindu
Family Structure Observed:
Predominantly joint families
Marital Duration Observed:
10–25 years
Number of Children Reported:
Mostly 2–3 children
Research Setting:
Rural village community
Keywords:
Contraceptives, experience of contraceptives, choices of contraceptives
Year:
2026
Region / City:
Israel
Topic:
Halacha, Contraception, Jewish Law
Document Type:
Shiur / Lecture Text
Institution:
Yeshivat Har Etzion, Koschitzky Virtual Beit Midrash
Author:
Laurie Novick
Editors:
Rav Ezra Bick, Ilana Elzufon, Shayna Goldberg
Audience:
Adult learners, students of Halacha
Period Covered:
Biblical times to modern contraceptive methods
Date Published:
2026
References:
Bereishit 38:7-10, Yevamot 34b, Nidda 13a, Tosafot Sanhedrin 59b, Tosafot Yevamot 12b, Rosh Ketubot 39a, Masechet Kalla Rabbati 2:7
Legal Focus:
Prohibition of hotza’at zera le-vatala, Hashchatat Zera, permissibility of contraceptive methods according to Halacha
Year:
2024
Regulatory authority:
Therapeutic Goods Administration (TGA)
Medicine:
MACITENTAN 10 mg with TADALAFIL 40 mg (Opsynvi®)
Indication:
Pulmonary arterial hypertension (PAH), WHO Group 1, functional class II and III
Therapy type:
Dual or triple combination therapy
Dosage form:
Tablet, fixed dose combination (FDC)
Prescriber type:
Medical practitioners
Restriction type:
Authority Required (Written, Complex Authority Required)
Clinical criteria:
Treatment as dual therapy (MAC+TAD) or triple therapy with prostanoid
Population:
Adult patients with stable PAH on separate doses of macitentan and tadalafil
Previous considerations:
PBAC recommendations for macitentan and tadalafil since 2011–2014
Approval date:
16 September 2024
Source documents:
TGA registration, PBAC meeting minutes, ACM minutes August 2024, FDA, EMA, CDA references
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Year:
2020
Region / City:
Elbonia
Meeting:
3GPP TSG-RAN WG2 #112
Document Type:
Technical report
Source / Organization:
Nokia, Nokia Shanghai Bell
Agenda Item:
5.4.3
Purpose:
Discussion and Decision
Scope:
Analysis of bandwidth combination sets (BWCS) for inter-ENDC and intra-ENDC configurations
Relevant Standards:
TS 38.101-1, TS 38.101-2, TS 38.101-3, TS 38.306
Deadline:
Short
Section:
26 13 13
Voltage class:
5 kV–15 kV
Document type:
Technical specification
Subject:
Medium-voltage switch-circuit breaker combination switchgear
Equipment type:
Metal-enclosed load-interrupter switchgear with vacuum circuit breakers
Applicable standards:
ANSI/IEEE C37 series; CSA 22.2 series; UL or C-UL listing
Frequency:
50 Hz; 60 Hz
System configuration:
Three-phase, grounded-neutral, ungrounded, or high-impedance grounded
Installation type:
Indoor or outdoor metal-enclosed switchgear
Manufacturer requirements:
Minimum five years experience; ISO 9001 or 9002 certification
Switchgear ratings:
Main bus up to 2000 A; short-time current up to 38 kA
Circuit breaker ratings:
5.0 kV and 15.0 kV classes with specified BIL and current ratings
Submittals required:
Shop drawings, wiring diagrams, schematics, bills of material, manuals
Construction requirements:
Factory-assembled metal-enclosed construction per IEEE C37.20.3
Storage and handling:
In accordance with manufacturer recommendations
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical benefits, chemotherapy, PBS
Document Type:
FAQ
Organization:
Pharmaceutical Benefits Scheme
Author:
Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience:
Healthcare providers, prescribers, patients
Effective Period:
From December 1, 2024
Approval Date:
Not specified
Modification Date:
Not specified
Contextual Description:
FAQ document providing detailed information on the changes in PBS listing for Opdualag and Vyxeos under the EFC Program, including prescription and claiming details.
Year:
2023
Region / City:
Global
Theme:
Assistive Technology, Braille Displays
Document Type:
User Manual
Organization:
APH (American Printing House for the Blind)
Author:
APH
Target Audience:
Users of iOS devices with braille needs
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2022
Region / city:
Australia
Topic:
Therapeutic Goods Regulation
Document type:
Guidance
Organization:
Therapeutic Goods Administration (TGA)
Author:
Commonwealth of Australia
Target audience:
Sponsors, manufacturers, and regulatory professionals
Validity period:
Not specified
Approval date:
October 2022
Date of changes:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Cancer Treatment / Immunotherapy
Document Type:
Submission
Organ / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Bristol-Myers Squibb
Target Audience:
Medical professionals, healthcare policy makers, pharmaceutical industry stakeholders
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2022
Subject:
Machine Learning, Ensemble Methods, Unsupervised Learning
Document Type:
Educational Unit / Lecture Notes
Author:
Not specified
Target Audience:
Students and researchers in machine learning
Techniques Covered:
Model combination, Voting schemes, Bagging, Boosting, Stacking, K-means clustering, K-nearest neighbors, Gaussian mixture models, Expectation maximization
Scope:
Theoretical explanation of ensemble learning and unsupervised methods, including algorithm generation and combination strategies
Year:
2024
Region / City:
United States
Topic:
Vaccination Protocol
Document Type:
Medical Protocol
Organization / Institution:
American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP)
Author:
Prescriber
Target Audience:
Healthcare professionals
Period of validity:
Indefinite until rescinded
Approval Date:
March 26, 2024
Date of changes:
Not specified
Year:
2018
Institution:
The George Washington University Cancer Center
Document Type:
Research Protocol Template
Study Phase:
Phase II
Principal Investigator:
Not specified
Co-Investigators:
Not specified
Statistician:
Not specified
Sponsor:
The George Washington University Cancer Center
Support/Grant:
Not specified
Supplied Agents:
Not specified
Other Agents:
Not specified
Study Number:
Assigned by GW Cancer Center
Location:
Washington, DC, USA
Year:
2023
Region / City:
East Lansing, Michigan
Subject:
Nuclear Physics, Bayesian Methods
Document Type:
Research Paper
Organization / Institution:
Facility for Rare Isotope Beams, Michigan State University, Department of Physics and Astronomy, Michigan State University
Authors:
Knight, Bailey, Lalit, Sudhanva, Godbey, Kyle, Giuliani, Pablo, Nazarewicz, Witold
Target Audience:
Nuclear physicists, researchers in astrophysics
Period of Effectiveness:
N/A
Approval Date:
N/A
Modification Date:
N/A
Contextual Description:
A research paper exploring the use of heteroscedastic uncertainties in Bayesian nuclear model combination, aiming to enhance predictive performance in nuclear physics models.
Year:
2022
Region / City:
N/A
Topic:
Fire & Smoke Damper Testing
Document Type:
Training Aid
Organization:
National Energy Management Institute Committee
Target Audience:
Contractors, Supervisors, Technicians, FLS Supervisors
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Applicable Standards:
NFPA 80 – 2022, NFPA 105 – 2012, NFPA 92 – 2018
Inspection Frequency:
Periodic
Document Purpose:
Guide for developing inspection methods and procedures for FLS dampers
Year:
2015
Region / City:
OECD
Topic:
Endocrine disruption, Aromatase inhibition, Reproductive dysfunction in fish
Document Type:
Review report
Organization / Institution:
OECD
Author:
Not specified
Target Audience:
Researchers, Environmental regulators, Toxicologists
Period of validity:
Not specified
Approval Date:
Not specified
Date of revisions:
September 2015